Merck Clinical Trials Logo Merck Clinical Trials

Clinical Trials

Merck Clinical Trials
  • About clinical trials
    • About Clinical Trials
    • How does participation work?
    • What to consider
    • Frequently asked questions
  • Resources
    • Resources
    • For patients
    • For caregivers
  • Our medical science
  • For HCPs
  • English
    • Back
    • English
    • Español

Umbrella Protocol: Keymaker U01

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-4830 in treatment-naïve participants with advanced squamous or non-squamous NSCLC that is PD-L1 positive.

This study is one of three pembrolizumab substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).

The pembrolizumab+MK-0482 arm was added with Amendment 6.

KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 Positive Advanced Non-small Cell Lung Cancer

October 9, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) in combination with MK-4830 in treatment-naïve participants with advanced squamous or non-squamous NSCLC that is PD-L1

KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Advanced Non-small Cell Lung Cancer

October 9, 2022

By clique_admin

This study is referred to as the “umbrella master protocol” for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform

KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer

October 9, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of pembrolizumab (MK-3475) PLUS chemotherapy in combination with vibostolimab (MK-7684), boserolimab (MK-5890), MK-4830, or MK-0482 in treatment-naïve participants with

Merck Clinical Trials Logo Merck Clinical Trials
  • Merck.com
  • Privacy Policy
  • Terms of Use
  • Policies & Perspectives
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

THIS WEBSITE IS INTENDED FOR A UNITED STATES AUDIENCE ONLY

Merck Essential Accessibility

Merck Essential Accessibility